Effect of a Novel Adenosine A2a Receptor Antagonist MB204 on Tau Hyperhosphorylation In Vivo

Multiple Tau epitopes were studied. In the cortex: reductions were seen in the phosphorylation at AT270, AT8 were seen in both MB204 and Li treatment (both p<0.001). A reduction was only seen with MB204 for pT205 (p<0.001) and only seen with lithium for the pS409 epitope (p<0.001). In the hippocampus: reductions were seen in the phosphorylation at pS40K were seen in both MB204 and Li treatment (both p<0.05 and 0.001 respectively). A reduction was only seen with MB204 for the AT8 epitope (p<0.05) and only seen for lithium for the AT270 and pT205 epitope (p<0.01 and 0.001) CONCLUSION: Acute oral treatment of mice with MB204 reduced anesthesia induced Tau hyperphosphorylation at key clinically relevant Tau epitopes. These findings highlight MB204 potential as a therapeutic agent for AD and related tauopathies.

Authors

Institutions

Publication Details

Journal
Alzheimer s & Dementia
Published
2025-12-01
DOI
https://doi.org/10.1002/alz70859_103170
Primary Topic
Adenosine and Purinergic Signaling
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Effect of a Novel Adenosine A2a Receptor Antagonist MB204 on Tau Hyperhosphorylation In Vivo

Mark Stephen Williams, Francis Laliberté, Emmanuel Planel, Geoffrey Canet et al.
Alzheimer s & Dementia
Adenosine and Purinergic Signaling
article

Effect of a Novel Adenosine A2a Receptor Antagonist MB204 on Tau Hyperhosphorylation In Vivo

Mark Stephen Williams, Francis Laliberté, Emmanuel Planel, Geoffrey Canet, Sofia Diego‐Diaz
article en

Abstract

Multiple Tau epitopes were studied. In the cortex: reductions were seen in the phosphorylation at AT270, AT8 were seen in both MB204 and Li treatment (both p<0.001). A reduction was only seen with MB204 for pT205 (p<0.001) and only seen with lithium for the pS409 epitope (p<0.001). In the hippocampus: reductions were seen in the phosphorylation at pS40K were seen in both MB204 and Li treatment (both p<0.05 and 0.001 respectively). A reduction was only seen with MB204 for the AT8 epitope (p<0.05) and only seen for lithium for the AT270 and pT205 epitope (p<0.01 and 0.001) CONCLUSION: Acute oral treatment of mice with MB204 reduced anesthesia induced Tau hyperphosphorylation at key clinically relevant Tau epitopes. These findings highlight MB204 potential as a therapeutic agent for AD and related tauopathies.

Alzheimer s & DementiaVol. 21(S5)
Centre hospitalier universitaire de Québec (CA), Centre hospitalier de l'Université Laval (CA), Université Laval (CA), Marvell (Israel) (IL)
Good health and well-being
Openalex Percentile: Top 35%
Adenosine and Purinergic Signaling
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Effect of a Novel Adenosine A2a Receptor Antagonist MB204 on Tau Hyperhosphorylation In Vivo — Mark Stephen Williams, Francis Laliberté, et al. · Alzheimer s & Dementia (2025) | TGRS Research Map | TGRS